All In Biotech

Drug Trial Radar · NCT01972568

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Jan 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

306

Actual

Start

Dec 2013

Primary completion

Apr 2016

Study completion Sep 2016

Sponsor

Lead sponsor
EMD SeronoIndustry
Sponsor type
Industry
First posted
Oct 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).

Conditions

  • Lupus Erythematosus, Systemic

Interventions

  • Atacicept 75 milligram (mg)Drug

    Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.

  • Atacicept 150 mgDrug

    Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.

  • PlaceboDrug

    Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as BaselineTime frame: Week 24
  2. Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Day 1 as BaselineTime frame: Week 24

Locations

138 sites in 18 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group LLC

    Anniston, Alabama

  • Achieve Clinical Research, LLC

    Birmingham, Alabama

  • University of Alabama at Birmingham - (UAB)

    Birmingham, Alabama

  • Southern California Permanente Medical Group

    Anaheim, California

  • Wallace Rheumatic Study Center

    Los Angeles, California

  • East Bay Rheumatology Medical Group, Inc.

    San Leandro, California

  • Clinical Research of West Florida - Corporate

    Dunedin, Florida

  • Center for Rheumatology, Immunology & Arthritis

    Fort Lauderdale, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Clinical Research of West Florida, Inc.

    Tampa, Florida

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • North MS Medical Clinics, Inc.

    Tupelo, Mississippi

  • Washington University School of Medicine

    St Louis, Missouri

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • The Feinstein Institute for Medical Research

    Manhasset, New York

  • Hospital for Special Surgery

    New York, New York

  • Box Arthritis & Rheumatology of the Carolinas PLLC

    Charlotte, North Carolina

  • MetroHealth System

    Cleveland, Ohio

  • Ohio State University Medical Center

    Columbus, Ohio

  • STAT Research, Inc.

    Dayton, Ohio

  • Arthritis & Rheumatology Center of Oklahoma

    Oklahoma City, Oklahoma

  • OMRF

    Oklahoma City, Oklahoma

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Clinical Research Center of Reading LLC

    Wyomissing, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • UTMB Pathology Clinical Services

    Galveston, Texas

  • Arthritis & Osteoporosis Clinic

    Waco, Texas

  • Danville Orthopedic Clinic, Inc.

    Danville, Virginia

  • APRILLUS

    Ciudad Autonoma Buenos Aires, Argentina

  • Atencion Integral en Reumatologia (AIR)

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Italiano

    Ciudad Autonoma Buenos Aires, Argentina

  • Organizacion Medica de Investigacion (OMI)

    Ciudad Autonoma Buenos Aires, Argentina

  • Policlìnica Red Omip S.A - Ensayos Clinicos GC

    Mar del Plata, Argentina

  • Centro de Investigacion Pergamino SA

    Pergamino, Argentina

  • Cordis S.A.

    Salta, Argentina

  • Centro Polivalente de Asistencia e Inv. Clinica CER

    San Juan, Argentina

  • Centro Integral de Reumatologia

    San Miguel de Tucumán, Argentina

  • Centro Medico Privado de Reumatologia

    San Miguel de Tucumán, Argentina

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.